Sutro Biopharma
IPO News: File S-1: Sutro Biopharma Files $75mm IPO

Sutro Biopharma


Initial Filing Date:  08/29/18

Size:  $75mm

Bookrunners:  Cowen | Piper Jaffray

Co-managers: JPM Securities | Wedbush PacGrow

Major Holders:  Alta Partners | Celgene Corp | Citadel | Lilly Ventures | Merck Sharp & Dohme Corp. | Samsara BioCapital | Skyline Venture | SV Health Investors | Vida Ventures | Named Executives 

Description: Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on leveraging their proprietary integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders.

Note: Emerging Growth Company

Reference Link:  S-1